Ken Frazier Joins Former Merck & Co Colleagues At Eikon Therapeutics
Becomes Start-Up’s First Independent Board Member
Executive Summary
Frazier has answered the call from Roger Perlmutter, his former head of R&D at Merck, to help the mysterious new biotech develop its platform.
You may also be interested in...
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
From Supertankers To Speedboats: Executives Make The Leap From Big Pharma To Start-Ups
Vir’s George Scangos, Westlake Village BioPartners’ Sean Harper, Kronos Bio’s Norbert Bischofberger, Scorpion’s Axel Hoos and Eikon’s Roy Baynes discuss the experiences they bring and the challenges they have faced in the transition from large drug makers to small biotechs.
Merck & Co.'s Barr To Lead Clinical Development After Baynes Departs For Eikon
Longtime R&D leader Roy Baynes is leaving Merck to become chief medical officer at the biotech start-up helmed by Merck's former R&D chief Roger Perlmutter.